Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
Anna Morena D’Alise(Nouscom (Italy)), Elisa Scarselli(Nouscom (Italy)), Fulvia Troise(Nouscom (Italy)), Rosa Bartolomeo(Dulbecco Telethon Institute), Elisa Micarelli(University of Rome Tor Vergata), Alfredo Nicosia(Ospedale Antonio Cardarelli), Linda Nocchi(European Molecular Biology Laboratory), Deborah H. Charych(Lawrence Berkeley National Laboratory), Guido Leoni(Nouscom (Italy)), Maria De Lucia(Nouscom (Italy)), Irene Garzia(Nouscom (Italy)), Veronica Bignone(Nouscom (Italy)), Francesca Langone(Nouscom (Italy)), Elena Di Matteo(Nouscom (Italy)), Gabriella Cotugno(Nouscom (Italy)), Fabio Giovanni Tucci(Nouscom (Italy)), Armin Lahm(IRBM Science Park), Rosa Vitale(Nouscom (Italy)), Jonathan Zalevsky(Nektar Therapeutics (United States))
Cited by 13
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403
Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man
|Science Translational Medicine|2012|401